Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness

CNS Drugs

Volumn 23, Issue SUPPL. 1, 2009, Pages 43-49

  Scahill, Lawrence ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; GUANFACINE; METHYLPHENIDATE; NORADRENALIN; PLACEBO;

ABDOMINAL PAIN; AGGRESSION; AROUSAL; ATTENTION DEFICIT DISORDER; AUTISM; AUTOMUTILATION; BEDTIME DOSAGE; BLOOD PRESSURE; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DECREASED APPETITE; DEVELOPMENTAL DISORDER; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DROWSINESS; DRUG BINDING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HALLUCINATION; HEART RATE; HUMAN; HYPERACTIVITY; HYPERTENSION; IMPULSIVENESS; INSOMNIA; IRRITABILITY; LOCUS CERULEUS; MANIA; MONOTHERAPY; MORNING DOSAGE; NORADRENERGIC NERVE; PREFRONTAL CORTEX; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHOOL CHILD; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUBSTANCE ABUSE; SYSTOLIC BLOOD PRESSURE; TIC; TREATMENT OUTCOME; VISUAL DISORDER;

ADRENERGIC ALPHA-AGONISTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CLONIDINE; GUANFACINE; HUMANS; IMPULSIVE BEHAVIOR;

EID: 67849121009     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/00023210-200923000-00006     Document Type: Review

References (36)

1. Cohen DJ, Young JG, Nathanson JA, et al. Clonidine in Tourette's syndrome. Lancet 1979; 2 (8142): 551-3
2. Gold MS, Redmond Jr DE, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 1978; 2 (8090): 599-602
3. Riddle MA, Bernstein GA, Cook EH, et al. Anxiolytics, adrenergic agents, and naltrexone. J Am Acad Child Adolesc Psychiatry 1999; 38 (5): 546-56
4. Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996; 53 (5): 448-55
5. Arnsten AFT. Alpha-2 agonists in the treatment of ADHD. Medscape Psychiatry & Mental Health 2007 [online]. Available from URL: http://www.medscape.com/viewarticle/560074 [Accessed 2008 Aug 24]
6. Wang M, Ramos BP, Paspalas CD, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007; 129 (2): 397-410
7. Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci 1988; 8 (11): 4287-98
8. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 1985; 24 (5): 617-29
9. MacDonald E, Kobilka BK, Scheinin M. Gene targeting - homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol Sci 1997; 18 (6): 211-9
10. Rubia K, Smith AB, Brammer MJ, et al. Right inferior prefrontal cortex mediates response inhibition while mesial prefrontal cortex is responsible for error detection. Neuro-image 2003; 20 (1): 351-8
11. Jakala P, Riekkinen M, Sirvio J, et al. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology 1999; 20 (5): 460-70
12. Arnsten AFT. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009; 23 Suppl. 1: 33-41
13. Balldin J, Berggren U, Eriksson E, et al. Guanfacine as an alpha-2-agonist inducer of growth hormone secretion - a comparison with clonidine. Psychoneuroendocrinology 1993; 18 (1): 45-55
14. Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens 2007;9 (5): 399-405
15. Sarlis NJ, Caticha O, Anderson JL, et al. Hyperadrenergic state following acute withdrawal from clonidine used at supra therapeutic doses. Clin Auton Res 1996; 6 (2): 115-7
16. Westfall T, Westfall D. Adrenergic agonists and antagonists. In: Brunton L, Lazo J, Parker K, editors. Goodman & Gilman's the pharmaceutical basis of therapeutics. New York (NY): McGraw-Hill, 2008: 237-96
17. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38 (12): 1551-9
18. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158 (7): 1067-74
19. Tourette syndrome (TS) Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58 (4): 527-36
20. Cummings DD, Singer HS, Krieger M, et al. Neuro-psychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol 2002; 25 (6): 325-32
21. Palumbo DR, Sallee FR, Pelham Jr WE, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47 (2): 180-8
22. Handen BL, Sahl R, Hardan AY. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr 2008; 29 (4): 303-8
23. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008; 121 (1): e73-84
24. Sallee FR, McGough J, Wigal T, et al., for the SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48 (2): 155-65
25. Scahill L, Erenberg G, Berlin CM, et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006; 3 (2): 192-206
26. Multimodal Treatment Study of Children with Attention-Deficit/ Hyperactivity Disorder (MTA) Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multi-modal Treatment Study of children with Attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1088-96
27. Daviss WB, Patel NC, Robb AS, et al. Clonidine for attention-deficit/ hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008; 47 (2): 189-98
28. Hunt RD, Arnsten AFT, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34: 50-4
29. Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995; 34: 1140-6
30. Horrigan JP, Barnhill LJ. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 1995; 5: 215-23
31. DuPaul GJ, Ervin RA, Hook CL, et al. Peer tutoring for children with attention deficit hyperactivity disorder: effects on classroom behavior and academic performance. J Appl Behav Anal 1998; 31: 579-92
32. Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985; 89 (5): 485-91
33. Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16 (5): 589-98
34. Boreman CD, Arnold LE. Hallucinations associated with initiation of guanfacine. J Am Acad Child Adolesc Psychiatry 2003; 42 (12): 1387
35. Luthra V, Markov D, Ambrosini P. Does guanfacine cause hallucinations in children? J Child Adolesc Psychopharmacol 1999; 9 (4): 313-4
36. Horrigan JP, Barnhill LJ. Guanfacine and secondary mania in children. J Affect Disord 1999; 54 (3): 309-14